These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 32073845)

  • 1. Discovery of 4-((2
    Mainolfi N; Ehara T; Karki RG; Anderson K; Mac Sweeney A; Liao SM; Argikar UA; Jendza K; Zhang C; Powers J; Klosowski DW; Crowley M; Kawanami T; Ding J; April M; Forster C; Serrano-Wu M; Capparelli M; Ramqaj R; Solovay C; Cumin F; Smith TM; Ferrara L; Lee W; Long D; Prentiss M; De Erkenez A; Yang L; Liu F; Sellner H; Sirockin F; Valeur E; Erbel P; Ostermeier D; Ramage P; Gerhartz B; Schubart A; Flohr S; Gradoux N; Feifel R; Vogg B; Wiesmann C; Maibaum J; Eder J; Sedrani R; Harrison RA; Mogi M; Jaffee BD; Adams CM
    J Med Chem; 2020 Jun; 63(11):5697-5722. PubMed ID: 32073845
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Small-molecule factor D inhibitors selectively block the alternative pathway of complement in paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome.
    Yuan X; Gavriilaki E; Thanassi JA; Yang G; Baines AC; Podos SD; Huang Y; Huang M; Brodsky RA
    Haematologica; 2017 Mar; 102(3):466-475. PubMed ID: 27810992
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A novel antibody against human factor B that blocks formation of the C3bB proconvertase and inhibits complement activation in disease models.
    Subías M; Tortajada A; Gastoldi S; Galbusera M; López-Perrote A; Lopez Lde J; González-Fernández FA; Villegas-Martínez A; Dominguez M; Llorca O; Noris M; Morgan BP; Rodríguez de Córdoba S
    J Immunol; 2014 Dec; 193(11):5567-75. PubMed ID: 25355917
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Small-molecule factor B inhibitor for the treatment of complement-mediated diseases.
    Schubart A; Anderson K; Mainolfi N; Sellner H; Ehara T; Adams CM; Mac Sweeney A; Liao SM; Crowley M; Littlewood-Evans A; Sarret S; Wieczorek G; Perrot L; Dubost V; Flandre T; Zhang Y; Smith RJH; Risitano AM; Karki RG; Zhang C; Valeur E; Sirockin F; Gerhartz B; Erbel P; Hughes N; Smith TM; Cumin F; Argikar UA; Haraldsson B; Mogi M; Sedrani R; Wiesmann C; Jaffee B; Maibaum J; Flohr S; Harrison R; Eder J
    Proc Natl Acad Sci U S A; 2019 Apr; 116(16):7926-7931. PubMed ID: 30926668
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design and Rationale of the APPELHUS Phase 3 Open-Label Study of Factor B Inhibitor Iptacopan for Atypical Hemolytic Uremic Syndrome.
    Kavanagh D; Greenbaum LA; Bagga A; Karki RG; Chen CW; Vasudevan S; Charney A; Dahlke M; Fakhouri F
    Kidney Int Rep; 2023 Jul; 8(7):1332-1341. PubMed ID: 37441479
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery of Highly Potent and Selective Small-Molecule Reversible Factor D Inhibitors Demonstrating Alternative Complement Pathway Inhibition in Vivo.
    Lorthiois E; Anderson K; Vulpetti A; Rogel O; Cumin F; Ostermann N; Steinbacher S; Mac Sweeney A; Delgado O; Liao SM; Randl S; Rüdisser S; Dussauge S; Fettis K; Kieffer L; de Erkenez A; Yang L; Hartwieg C; Argikar UA; La Bonte LR; Newton R; Kansara V; Flohr S; Hommel U; Jaffee B; Maibaum J
    J Med Chem; 2017 Jul; 60(13):5717-5735. PubMed ID: 28621538
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Design, Synthesis, and Preclinical Characterization of Selective Factor D Inhibitors Targeting the Alternative Complement Pathway.
    Karki RG; Powers J; Mainolfi N; Anderson K; Belanger DB; Liu D; Ji N; Jendza K; Gelin CF; Mac Sweeney A; Solovay C; Delgado O; Crowley M; Liao SM; Argikar UA; Flohr S; La Bonte LR; Lorthiois EL; Vulpetti A; Brown A; Long D; Prentiss M; Gradoux N; de Erkenez A; Cumin F; Adams C; Jaffee B; Mogi M
    J Med Chem; 2019 May; 62(9):4656-4668. PubMed ID: 30995036
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Autoantibodies to complement components in C3 glomerulopathy and atypical hemolytic uremic syndrome.
    Józsi M; Reuter S; Nozal P; López-Trascasa M; Sánchez-Corral P; Prohászka Z; Uzonyi B
    Immunol Lett; 2014 Aug; 160(2):163-71. PubMed ID: 24491679
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Overactivity of Alternative Pathway Convertases in Patients With Complement-Mediated Renal Diseases.
    Michels MAHM; van de Kar NCAJ; Okrój M; Blom AM; van Kraaij SAW; Volokhina EB; van den Heuvel LPWJ
    Front Immunol; 2018; 9():612. PubMed ID: 29670616
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A bispecific inhibitor of complement and coagulation blocks activation in complementopathy models via a novel mechanism.
    Andersen JF; Lei H; Strayer EC; Kanai T; Pham V; Pan XZ; Alvarenga PH; Gerber GF; Asojo OA; Francischetti IMB; Brodsky RA; Valenzuela JG; Ribeiro JMC
    Blood; 2023 Jun; 141(25):3109-3121. PubMed ID: 36947859
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Low-molecular weight inhibitors of the alternative complement pathway.
    Schubart A; Flohr S; Junt T; Eder J
    Immunol Rev; 2023 Jan; 313(1):339-357. PubMed ID: 36217774
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The lectin self of complement factor H.
    Blaum BS
    Curr Opin Struct Biol; 2017 Jun; 44():111-118. PubMed ID: 28189794
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Be on Target: Strategies of Targeting Alternative and Lectin Pathway Components in Complement-Mediated Diseases.
    Dobó J; Kocsis A; Gál P
    Front Immunol; 2018; 9():1851. PubMed ID: 30135690
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery of 2-methyl-1-{1-[(5-methyl-1H-indol-2-yl)carbonyl]piperidin-4-yl}propan-2-ol: a novel, potent and selective type 5 17β-hydroxysteroid dehydrogenase inhibitor.
    Watanabe K; Kakefuda A; Yasuda M; Enjo K; Kikuchi A; Furutani T; Naritomi Y; Otsuka Y; Okada M; Ohta M
    Bioorg Med Chem; 2013 Sep; 21(17):5261-70. PubMed ID: 23845281
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Complement activation in diseases presenting with thrombotic microangiopathy.
    Meri S
    Eur J Intern Med; 2013 Sep; 24(6):496-502. PubMed ID: 23743117
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Increased enzymatic activity of the alternative pathway convertase when bound to the erythrocytes of paroxysmal nocturnal hemoglobinuria.
    Parker CJ; Baker PJ; Rosse WF
    J Clin Invest; 1982 Feb; 69(2):337-46. PubMed ID: 6915939
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Complement System Abnormalities in Patients with Atypical Hemolytic Uremic Syndrome and Catastrophic Antiphospholipid Syndrome].
    Demyanova KA; Kozlovskaya NL; Bobrova LA; Kozlov LV; Andina SS; Yurova VA; Kuchieva AM; Roshchupkina SV; Shilov EM
    Vestn Ross Akad Med Nauk; 2017; 72(1):42-52. PubMed ID: 29308852
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapeutic complement inhibition in complement-mediated hemolytic anemias: Past, present and future.
    Risitano AM; Marotta S
    Semin Immunol; 2016 Jun; 28(3):223-40. PubMed ID: 27346521
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Profiling the enzymatic properties and inhibition of human complement factor B.
    Le GT; Abbenante G; Fairlie DP
    J Biol Chem; 2007 Nov; 282(48):34809-16. PubMed ID: 17921140
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Complement-driven anemia: more than just paroxysmal nocturnal hemoglobinuria.
    Merrill SA; Brodsky RA
    Hematology Am Soc Hematol Educ Program; 2018 Nov; 2018(1):371-376. PubMed ID: 30504334
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.